Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Dyne Therapeutics is a clinical-stage muscle disease biotechnology company developing FORCE platform therapies that combine oligonucleotides with antibody fragments to target muscle tissue. The company's lead programs include DYNE-101 for myotonic dystrophy type 1 (DM1) and DYNE-251 for Duchenne muscular dystrophy (DMD), with clinical trials ongoing as of early 2026. Stock performance is driven by clinical trial readouts, regulatory milestones, and cash runway visibility given zero current revenue.
Dyne operates as a clinical-stage biotech developing proprietary FORCE (Folding Receptor Constructs for Enhanced delivery) platform that conjugates oligonucleotides to antibody Fc domains, enabling targeted muscle delivery with potential for improved efficacy and reduced systemic exposure versus naked oligonucleotides. The company aims to generate revenue through commercialization of approved therapies for rare muscle diseases with high unmet need, commanding premium orphan drug pricing (estimated $300K-500K annually per patient). Competitive advantages include proprietary delivery technology, established clinical proof-of-concept data, and intellectual property protection around FORCE conjugation methods. Current cash burn approximately $120-140M annually supports multiple clinical programs through key inflection points.
Clinical trial data readouts for DYNE-101 (DM1) and DYNE-251 (DMD) - efficacy, safety, and muscle tissue penetration metrics
FDA regulatory interactions including IND clearances, Fast Track designations, and breakthrough therapy designations for lead programs
Cash runway updates and financing events (equity raises, partnerships) given $300M+ cash burn through potential commercialization
Competitive developments in oligonucleotide delivery platforms and rival DMD/DM1 programs from Sarepta, PepGen, and others
Partnership or licensing announcements leveraging FORCE platform for additional indications
Clinical trial failure risk - Phase 2/3 trials for DYNE-101 and DYNE-251 may not demonstrate sufficient efficacy or acceptable safety profiles, resulting in program termination and significant value destruction
Regulatory approval uncertainty - FDA may require additional studies, reject applications, or impose restrictive labels limiting commercial potential even with positive trial data
Oligonucleotide delivery competition - rival platforms (exon-skipping, gene therapy, alternative conjugation technologies) may demonstrate superior efficacy or safety, obsoleting FORCE platform advantages
Sarepta Therapeutics dominates DMD market with approved exon-skipping therapies and gene therapy, creating high bar for differentiation and potential market share capture
Multiple well-funded competitors developing DM1 therapies including Avidity Biosciences (AOC-1001) and Entrada Therapeutics, racing to establish first-mover advantage in nascent market
Large pharma partnerships with competitors (e.g., Roche-PepGen collaboration) provide resource advantages in clinical development and commercialization capabilities
Cash runway risk - with approximately $330M cash as of late 2025 and $120-140M annual burn, company faces potential need for dilutive financing within 18-24 months absent partnership revenue or capital markets access
Equity dilution risk - pre-revenue biotechs typically require multiple financing rounds, and adverse market conditions or clinical setbacks could force raises at unfavorable valuations, significantly diluting existing shareholders
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending follows scientific timelines rather than economic cycles. Patient enrollment in rare disease trials is driven by medical need, not discretionary spending. However, severe recessions can impact venture capital availability and public market valuations for pre-revenue biotechs.
Rising interest rates create significant headwinds through multiple channels: (1) higher discount rates compress NPV of distant future cash flows, disproportionately impacting pre-revenue companies with 5-7 year commercialization timelines, (2) risk-free rate competition makes speculative biotech investments less attractive versus bonds, (3) increased cost of capital for future financing rounds. The company's $330M+ cash position provides near-term buffer, but eventual need for additional capital makes rate environment critical for dilution risk.
Minimal direct credit exposure as the company operates with minimal debt (0.17 D/E ratio) and does not rely on credit markets for operations. However, broader credit market stress can impact biotech sector sentiment and ability to access capital markets for future equity raises needed to fund operations through commercialization.
growth - Attracts high-risk tolerance biotech specialists and growth investors seeking asymmetric returns from clinical-stage rare disease programs. Binary outcome profile (clinical success vs failure) appeals to venture-style public market investors willing to underwrite 5-7 year commercialization timelines. Not suitable for income or value investors given zero revenue, negative cash flow, and high volatility. Institutional ownership likely concentrated among specialized healthcare funds.
high - Clinical-stage biotechs exhibit extreme volatility with 50-80% single-day moves common around clinical data releases. Stock has demonstrated this pattern with -25.3% three-month decline followed by +25.6% six-month recovery. Beta likely exceeds 1.5x versus broader market, with idiosyncratic risk dominating systematic factors. Volatility will remain elevated until commercial revenue visibility emerges post-approval.
